Cite
HARVARD Citation
Curti, B. et al. (2017). Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry. Journal for immunotherapy of cancer. 5 (1), p. . [Online].